Phase 1/2A Dose Escalation Study in CLL, SLL or NHL
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070)
that may be given in patients with relapsed/refractory chronic lymphocytic leukemia or
non-hodgkin lymphoma